United Therapeutics (Nasdaq: UTHR) is selling a voucher designed to speed up approval for rare pediatric disease treatments to Chicago-based pharmaceutical company AbbVie Inc. for a record $350 million.
The Wall Street Journal reports the Silver Spring-based biotechnology company landed the voucher when it received approval from the Food and Drug Administration for Unituxin, its drug designed to treat neuroblastoma.
{iframe}http://www.bizjournals.com/washington/morning_call/2015/08/why-united-therapeutics-is-selling-priority-review.html?ana=e_wash_rdup&s=newsletter&ed=2015-08-19&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1440172124{/iframe}